[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gynaecological-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gynaecological-cancers":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100600714","gyngher---her2-expression-in-gynecological-malignancies-a-brazilian-cohort-100600714",false,"NCT07101081","GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort","GYNGHER","Inclusion Criteria:\n\n* Age \\>= 18 years at sample collection; - Diagnosis of cervical, endometrial, ovarian\u002Fperitoneum\u002Futerine tube, vulvar, or vaginal cancers;\n* Sufficient paraffin primary tumor tissue for biomarker testing in the OC Precision Medicine Pathology labs.\n* Date of diagnosis of gynecological cancer must be from January 2020 to March 2025.\n* Patients need to sign informed consent, or waiver of informed consent is granted.\n\nExclusion Criteria:\n\n* Patients without sufficient paraffin tissue for the proposed biomarker testing.\n* Patients whose diagnosis was performed in metastatic lesion.\n* Patients with history of exposure to systemic anti-cancer therapies for the gynecological cancer diagnosis before surgery or excisional biopsy of gynecological cancer (information is available in the original histopathology request document stored in the LIMS).","FEMALE",{"count":18,"type":19},350,"ESTIMATED","OBSERVATIONAL","Adult patients with gynecologic cancer (endometrial, ovarian, cervical, vulvar and vaginal cancers) treated at Oncoclínicas \\& CO sites will be enrolled for primary tumor immunohistochemistry (IHC) analysis. When sufficient paraffin tissue is available for biomarker testing, slides will be sent from partner Pathology Labs of the OC Precision Medicine network to Locus Lab (São Paulo) for HER2 staining with automated protocols (Dako HercepTest and Roche Ventana 4B5) and scoring using different criteria (gastric cancer, breast cancer, and endometrial cancer). Primary objective is to describe the prevalence of HER2 high expression (IHC 3+ using Dako HercepTest and gastric cancer scoring criteria) in endometrial, ovarian, and cervical cancers (common gynecological malignancies). Secondary objectives are to describe the prevalence of HER2 high expression (IHC 3+ using Dako HercepTest and gastric cancer scoring criteria) in vulvar and vaginal cancers (rare gynecological malignancies); and to describe the prevalence of different HER2 expression levels (IHC 0, 1+ and 2+ using Dako HercepTest and gastric cancer scoring criteria) across all gynecological malignancies, to describe HER2 expression levels as per endometrial cancer scoring criteria in the endometrial cohort; to describe the association of different histological subtypes of gynecological cancer with HER2 IHC expression levels.",[23],"Gynaecological Cancers",[25,26],"Gynaecological cancers","HER-2","RECRUITING","2026-06-26",{"date":30,"type":31},"2026-06-29","ACTUAL",{"date":33,"type":31},"2026-04-23",{"date":35,"type":19},"2026-11-11",{"name":37,"class":38},"AstraZeneca","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100639185","vaginal-fluid-derived-biomarkers-in-the-early-detection-and-evolution-of-gynaecological-cancers-100639185","NCT07622953","Vaginal Fluid Derived Biomarkers in the Early Detection and Evolution of Gynaecological Cancers","VIOLET","Inclusion Criteria:\n\n* Suspected cohort: Individuals undergoing investigations for suspected gynaecological cancer. This includes patients undergoing surgery to reduce their risk of the development of gynaecological cancers in the future\n* Confirmed treatment cohort: Individuals with a confirmed gynaecological cancer diagnosis undergoing anti-cancer treatment including surgical resection, chemotherapy or radiotherapy as part of their routine clinical care\n* Confirmed palliative cohort: Individuals with a confirmed gynaecological cancer diagnosis undergoing palliative procedures including ascitic drainage as part of their routine clinical care\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Individuals who lack capacity to consent to trial participation\n* Pregnant or breastfeeding patients\n* Patients with active vaginal infection\n* Patients currently on or having received antibiotics within the previous week\n* History of prior malignancy or chronic inflammatory disease","18 Years",{"count":49,"type":19},250,"This study will investigate vaginal secretions in those patients with cancer versus those who are cancer free and compare changes in specific markers that change when a cancer first develops.\n\nPatients who are being investigated for any gynaecological cancer, undergoing surgery to reduce their risk of gynaecological cancer and those with confirmed gynaecological cancer undergoing anti-cancer treatment will be approached to take part in this study.\n\nParticipants will be asked to provide an extra blood test, urine sample and high vaginal swab in addition to surplus primary tissue and ascitic fluid that is left over from routine surgical procedures. Specific markers will be compared in patients who have evidence of gynaecological cancer versus those that do not. Changes in these markers during anti-cancer treatment will also be compared to see how these change over time. This could improve the detection and monitoring of gynaecological cancers in those people at highest risk of developing it by using non-invasive multi-cancer early detection tests developed at the University of Southampton.",[23],[25,53,54],"Biomarker","Multi-Cancer Early Detection","2026-05-26",{"date":57,"type":31},"2026-06-03",{"date":59,"type":31},"2026-01-14",{"date":61,"type":19},"2030-07-02",{"name":63,"class":64},"University Hospital Southampton NHS Foundation Trust","OTHER"]